CUSIP: 81362J209
Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
2,789,461
-
Share change
-
+285,832
-
Total reported value
-
$8,894,000
-
Put/Call ratio
-
80%
-
Price per share
-
$3.19
-
Number of holders
-
36
-
Value change
-
+$889,921
-
Number of buys
-
12
-
Number of sells
-
2
Quarterly Holders Quick Answers
What is CUSIP 81362J209?
CUSIP 81362J209 identifies EYES - SECOND SIGHT MED PRODS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2021
-
Previous quarter:
Q2 2021
Recent filing periods for CUSIP 81362J209:
Institutional Holders of SECOND SIGHT MED PRODS INC - COM NEW (EYES) as of Q3 2021
As of 30 Sep 2021,
SECOND SIGHT MED PRODS INC - COM NEW (EYES) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,789,461 shares.
The largest 10 holders included
VANGUARD GROUP INC, SABBY MANAGEMENT, LLC, Hudson Bay Capital Management LP, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC, and Paloma Partners Management Co.
This page lists
36
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.